VISCERA IN SULFONYLUREA-TREATED DIABETICS

被引：0
|
作者：
WELLMANN, KF
LAZARUS, SS
VOLK, BW
机构：
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 1963年 / 12卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：959 / &
相关论文
共 50 条
  • [21] HEMOGLOBIN AL CORRELATES WITH THE LDL-HDL CHOLESTEROL RATIO IN SULFONYLUREA TREATED DIABETICS
    SCHMITT, JK
    KROOK, SB
    LEWIS, SB
    DIABETES, 1983, 32 : A81 - A81
  • [22] EFFECT OF SULFONYLUREA ON INSULIN-SECRETION AND GLUCOSE CONTROL IN INSULIN-TREATED DIABETICS
    WARD, EA
    WARD, GM
    TURNER, RC
    BRITISH MEDICAL JOURNAL, 1981, 283 (6286): : 278 - 278
  • [23] Effect of exenatide (exendin-4) on glycemic control and safety over 30 weeks in sulfonylurea-treated patients with Type 2 diabetes
    Buse, J
    Henry, R
    Han, J
    Kim, D
    Fineman, M
    Baron, AD
    DIABETOLOGIA, 2004, 47 : A280 - A280
  • [24] Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
    Buse, JB
    Henry, RR
    Han, J
    Kim, DD
    Fineman, MS
    Baron, AD
    DIABETES CARE, 2004, 27 (11) : 2628 - 2635
  • [25] Results of a placebo-controlled study of the metabolic effects of the addition of metaformin to sulfonylurea-treated patients - Evidence for a central role of adipose tissue
    Abbasi, F
    Kamath, V
    Rizvi, AA
    Carantoni, M
    Chen, YDI
    Reaven, GM
    DIABETES CARE, 1997, 20 (12) : 1863 - 1869
  • [26] Effect of exenatide (exendin-4) on glycemic control and safety over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
    Buse, J
    Henry, R
    Han, J
    Kim, DD
    Fineman, M
    Baron, AD
    DIABETES, 2004, 53 : A82 - A82
  • [27] ADDITIONAL METABOLIC EFFECTS OF BENFLUOREX IN SULFONYLUREA-TREATED PATIENTS WITH TYPE-2 (NON-INSULIN-DEPENDENT) DIABETES-MELLITUS
    SINAY, IR
    ARIAS, P
    CAGIDE, A
    DAMILANO, S
    FAINGOLD, MC
    DIABETOLOGIA, 1989, 32 (07) : A541 - A541
  • [28] Risk of severe hypoglycemia in sulfonylurea-treated patients from diabetes centers in Germany/Austria: How big is the problem? Which patients are at risk?
    Schloot, Nanette C.
    Haupt, Axel
    Schuett, Morten
    Badenhoop, Klaus
    Laimer, Markus
    Nicolay, Claudia
    Reaney, Matthew
    Fink, Katharina
    Holl, Reinhard W.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2016, 32 (03) : 316 - 324
  • [29] Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated Type 2 diabetic patients
    Ragia, Georgia
    Tavridou, Anna
    Petridis, Ioannis
    Manolopoulos, Vangelis G.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 98 (01) : 119 - 124
  • [30] HYPERLIPEMIA FOLLOWING SULFONYLUREA THERAPY IN YOUNG DIABETICS
    SHIPP, JC
    WOOD, FC
    MARBLE, A
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1964, 188 (05): : 468 - &
12345